Frontotemporal Dementia (FTD) is a group of neurodegenerative disorders characterized by progressive deterioration of the frontal and temporal lobes of the brain. It presents with prominent changes in personality, behavior, and/or language, typically with onset before age 65. FTD is associated with abnormal accumulation of tau or TDP-43 proteins.
Ask a research question about Frontotemporal Dementia. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).
Do not include personal health information in your question. Questions and results are cached in your browser's local storage.
name: Frontotemporal Dementia
creation_date: '2025-12-23T16:19:20Z'
updated_date: '2026-02-17T21:53:14Z'
description: >
Frontotemporal Dementia (FTD) is a group of neurodegenerative disorders characterized
by progressive deterioration of the frontal and temporal lobes of the brain. It
presents
with prominent changes in personality, behavior, and/or language, typically with
onset
before age 65. FTD is associated with abnormal accumulation of tau or TDP-43 proteins.
category: Complex
disease_term:
preferred_term: frontotemporal dementia
term:
id: MONDO:0017276
label: frontotemporal dementia
parents:
- Dementia
- Neurodegenerative Disease
pathophysiology:
- name: TDP-43 Proteinopathy
description: >
TAR DNA-binding protein of 43 kDa (TDP-43) is the main ubiquitinated protein
in tau-negative frontotemporal lobar degeneration (FTLD-TDP), accounting for
over 50% of FTD cases. TDP-43 is typically a nuclear protein, and its aggregation
and cytoplasmic translocation are thought to represent major pathogenic steps.
The abnormal accumulation leads to neuronal dysfunction and death.
cell_types:
- preferred_term: neuron
term:
id: CL:0000540
label: neuron
downstream:
- target: Neuronal Death
- target: Behavioral and Language Changes
evidence:
- reference: PMID:19664364
reference_title: "TDP-43 and frontotemporal dementia."
supports: SUPPORT
snippet: TDP-43 is typically a nuclear protein, and its aggregation and
cytoplasmic translocation are thought to represent major steps in the
pathogenesis of FTLD due to TDP-43 proteinopathy (FTLD-TDP).
explanation: This confirms that TDP-43 aggregation and mislocalization are
central to the pathogenesis of FTLD-TDP, a major subtype of frontotemporal
dementia.
- name: Tau Proteinopathy
description: >
FTLD-tau is characterized by accumulation of hyperphosphorylated tau protein,
accounting for approximately 45% of FTD cases. This includes Pick's disease
with characteristic Pick bodies. The tau pathology disrupts microtubule function
and causes neuronal degeneration primarily in frontal and temporal regions.
cell_types:
- preferred_term: neuron
term:
id: CL:0000540
label: neuron
downstream:
- target: Neuronal Death
- target: Behavioral and Language Changes
- name: Frontal and Temporal Lobe Atrophy
description: >
Progressive neuronal loss and atrophy predominantly affecting the frontal and
temporal lobes, with patterns varying by genetic subtype. MAPT mutations show
temporal predominance, while GRN and C9orf72 mutations may show more variable
patterns. This structural degeneration underlies the behavioral and language deficits.
cell_types:
- preferred_term: neuron
term:
id: CL:0000540
label: neuron
downstream:
- target: Behavioral Variant FTD
- target: Primary Progressive Aphasia
evidence:
- reference: PMID:26473392
reference_title: "Distinct clinical and pathological phenotypes in frontotemporal dementia associated with MAPT, PGRN and C9orf72 mutations."
supports: SUPPORT
snippet: MAPT patients were younger than other groups, and showed more
frequent behavioural disinhibition, repetitive and stereotyped behaviours,
semantic impairment and temporal predominance of atrophy.
explanation: This demonstrates the genotype-specific patterns of brain
atrophy and their relationship to clinical phenotypes in frontotemporal
dementia.
- name: Neuronal Death
description: >
Progressive loss of neurons in frontal and temporal cortices due to protein
aggregation toxicity, leading to brain atrophy and functional decline. The
neurodegeneration progresses over years to decades, with biomarker changes
detectable up to 30 years before symptom onset in genetic cases.
cell_types:
- preferred_term: neuron
term:
id: CL:0000540
label: neuron
evidence:
- reference: PMID:30711676
reference_title: "Clinical and biomarker changes in presymptomatic genetic frontotemporal dementia."
supports: PARTIAL
snippet: We observed that biological changes and intracortical facilitation
transmission abnormalities significantly antecede the emergence of
clinical symptoms of at least 3 decades.
explanation: Supports long presymptomatic neurobiological change in genetic
FTD, but does not directly quantify neuronal death in the quoted text.
phenotypes:
- category: Neurological
name: Behavioral Changes
frequency: VERY_FREQUENT
diagnostic: true
notes: Prominent behavioral changes including disinhibition, apathy, loss of
empathy, compulsive behaviors, and dietary changes. Particularly
characteristic of behavioral variant FTD.
evidence:
- reference: PMID:26473392
reference_title: "Distinct clinical and pathological phenotypes in frontotemporal dementia associated with MAPT, PGRN and C9orf72 mutations."
supports: SUPPORT
snippet: MAPT patients were younger than other groups, and showed more
frequent behavioural disinhibition, repetitive and stereotyped behaviours,
semantic impairment and temporal predominance of atrophy.
explanation: This confirms that behavioral disinhibition and repetitive
stereotyped behaviors are core clinical features of genetic FTD,
particularly in MAPT mutations.
- category: Neurological
name: Aphasia
frequency: VERY_FREQUENT
diagnostic: true
notes: Progressive language impairment, particularly non-fluent aphasia in GRN
mutations and semantic variant primary progressive aphasia. Language
deficits may be the presenting feature.
evidence:
- reference: PMID:26473392
reference_title: "Distinct clinical and pathological phenotypes in frontotemporal dementia associated with MAPT, PGRN and C9orf72 mutations."
supports: SUPPORT
snippet: GRN patients were older at death and more likely to present with
non-fluent aphasia.
explanation: This demonstrates that non-fluent aphasia is a characteristic
presenting feature in patients with GRN mutations causing frontotemporal
dementia.
phenotype_term:
preferred_term: Aphasia
term:
id: HP:0002381
label: Aphasia
- category: Neurological
name: Personality Changes
frequency: VERY_FREQUENT
diagnostic: true
notes: Progressive changes in personality including social inappropriateness,
loss of emotional warmth, and altered social cognition. C9orf72 patients may
paradoxically appear socially warm despite other behavioral changes.
evidence:
- reference: PMID:26473392
reference_title: "Distinct clinical and pathological phenotypes in frontotemporal dementia associated with MAPT, PGRN and C9orf72 mutations."
supports: SUPPORT
snippet: They showed more psychotic symptoms and irrational behaviour, yet
were more often reported clinically as socially appropriate and warm.
explanation: This highlights the complex and sometimes paradoxical
personality changes in C9orf72-related FTD, where patients may retain
apparent social warmth despite significant behavioral dysfunction.
phenotype_term:
preferred_term: Personality changes
term:
id: HP:0000751
label: Personality changes
- category: Neurological
name: Dementia
frequency: VERY_FREQUENT
diagnostic: true
notes: Progressive cognitive decline affecting executive function, social
cognition, and behavior, with relatively preserved memory in early stages
compared to Alzheimer's disease.
phenotype_term:
preferred_term: Dementia
term:
id: HP:0000726
label: Dementia
genetic:
- name: MAPT
association: Mutations cause autosomal dominant FTD with tau pathology
notes: Microtubule-associated protein tau gene on chromosome 17q21. Mutations
lead to FTLD-tau pathology. Patients show earlier onset, prominent
behavioral disinhibition, stereotyped behaviors, and temporal lobe
predominance of atrophy.
evidence:
- reference: PMID:26473392
reference_title: "Distinct clinical and pathological phenotypes in frontotemporal dementia associated with MAPT, PGRN and C9orf72 mutations."
supports: SUPPORT
snippet: MAPT patients were younger than other groups, and showed more
frequent behavioural disinhibition, repetitive and stereotyped behaviours,
semantic impairment and temporal predominance of atrophy.
explanation: This confirms the distinct clinical and anatomical phenotype
associated with MAPT mutations in frontotemporal dementia.
- name: GRN
association: Mutations cause autosomal dominant FTD with TDP-43 pathology
notes: Progranulin gene on chromosome 17q21. Haploinsufficiency leads to
FTLD-TDP pathology. Patients more likely to present with non-fluent aphasia
and are older at symptom onset. GRN and C9orf72 are the most frequent
genetic causes.
evidence:
- reference: PMID:26473392
reference_title: "Distinct clinical and pathological phenotypes in frontotemporal dementia associated with MAPT, PGRN and C9orf72 mutations."
supports: SUPPORT
snippet: GRN patients were older at death and more likely to present with
non-fluent aphasia.
explanation: This demonstrates the characteristic clinical presentation of
GRN-related FTD with language deficits.
- reference: PMID:30711676
reference_title: "Clinical and biomarker changes in presymptomatic genetic frontotemporal dementia."
supports: SUPPORT
snippet: Presymptomatic carriers of GRN and C9orf72 mutations, the most
frequent genetic causes of frontotemporal lobar degeneration, represent
the optimal target population for the development of disease-modifying
drugs.
explanation: This confirms GRN as one of the two most common genetic causes
of FTD.
- name: C9orf72
association: Hexanucleotide repeat expansion causes autosomal dominant FTD,
often with ALS
notes: Hexanucleotide (GGGGCC) repeat expansion on chromosome 9p21. Most
common genetic cause of FTD. Causes FTLD-TDP pathology. Unique features
include co-occurrence with ALS, psychotic symptoms, and paradoxically
preserved social warmth.
evidence:
- reference: PMID:26473392
reference_title: "Distinct clinical and pathological phenotypes in frontotemporal dementia associated with MAPT, PGRN and C9orf72 mutations."
supports: SUPPORT
snippet: C9orf72 patients alone showed a co-occurrence of ALS. They showed
more psychotic symptoms and irrational behaviour, yet were more often
reported clinically as socially appropriate and warm.
explanation: This highlights the distinctive clinical features of
C9orf72-related FTD including the frequent association with ALS and unique
behavioral profile.
- reference: PMID:30711676
reference_title: "Clinical and biomarker changes in presymptomatic genetic frontotemporal dementia."
supports: SUPPORT
snippet: Presymptomatic carriers of GRN and C9orf72 mutations, the most
frequent genetic causes of frontotemporal lobar degeneration, represent
the optimal target population for the development of disease-modifying
drugs.
explanation: This confirms C9orf72 as one of the most common genetic causes
of FTD.
treatments:
- name: Symptomatic Management
description: No disease-modifying treatments currently available. Management
focuses on behavioral symptoms with selective serotonin reuptake inhibitors
for compulsive behaviors and agitation, and non-pharmacological approaches
including behavioral interventions and caregiver support.
treatment_term:
preferred_term: supportive care
term:
id: MAXO:0000950
label: supportive care
- name: Speech and Language Therapy
description: Speech therapy interventions for patients with language-variant
FTD to maintain communication abilities and quality of life for as long as
possible.
treatment_term:
preferred_term: supportive care
term:
id: MAXO:0000950
label: supportive care
classifications:
harrisons_chapter:
- classification_value: nervous system disorder
- classification_value: neurodegenerative disease
mechanistic_category:
- classification_value: tauopathy
datasets:
- accession: geo:GSE13162
title: Expression data from postmortem human brain samples with and without
FTLD-U
description: Microarray expression profiling of frontal cortex, hippocampus,
and cerebellum from FTLD-U and control brains.
organism:
preferred_term: human
term:
id: NCBITaxon:9606
label: Homo sapiens
data_type: MICROARRAY
sample_types:
- preferred_term: brain tissue
tissue_term:
preferred_term: brain
term:
id: UBERON:0000955
label: brain
sample_count: 56
conditions:
- frontotemporal lobar degeneration with ubiquitin-positive inclusions
- control brain tissue
notes: Includes 31 FTLD-U and 25 control samples.
references:
- reference: DOI:10.1093/brain/awae074
title: 'Synaptopathy: presynaptic convergence in frontotemporal dementia and amyotrophic
lateral sclerosis'
findings: []
- reference: DOI:10.1101/2024.02.09.579529
title: Alterations in Lysosomal, Glial and Neurodegenerative Biomarkers in
Patients with Sporadic and Genetic Forms of Frontotemporal Dementia
findings: []
- reference: DOI:10.1186/s12974-024-03039-1
title: Progranulin haploinsufficiency mediates cytoplasmic TDP-43 aggregation
with lysosomal abnormalities in human microglia
findings: []
- reference: DOI:10.1186/s40035-024-00429-6
title: 'Tau in neurodegenerative diseases: molecular mechanisms, biomarkers, and
therapeutic strategies'
findings: []
- reference: DOI:10.21203/rs.3.rs-4103685/v1
title: Large-scale network analysis of the cerebrospinal fluid proteome
identifies molecular signatures of frontotemporal lobar degeneration
findings: []
Pathophysiology description Frontotemporal dementia (FTD) encompasses frontotemporal lobar degeneration (FTLD) driven by distinct proteinopathies and convergent cellular stress pathways. The principal pathological classes are FTLD–TDP (abnormal TDP-43), FTLD–tau (abnormal MAPT/tau), and less commonly FTLD–FUS (abnormal FUS/FET proteins). Across genetic and sporadic forms, early synaptic failure—particularly at the presynapse—emerges as a convergent mechanism, followed by progressive neuronal loss and network disintegration in frontal and temporal cortices (paralimbic fronto–insular–striatal circuits) (overview; proportions and convergence on presynaptic dysfunction) (https://doi.org/10.1093/brain/awae074, Mar 2024) (clayton2024synaptopathypresynapticconvergence pages 1-2). Molecularly, risk genes and causal mutations perturb proteostasis (aggregation, phase transitions), RNA metabolism (splicing/transport), autophagy–lysosomal homeostasis, nucleocytoplasmic transport, and innate immune signaling. These processes interact: genetic and proteostatic stressors (e.g., C9orf72 repeat expansions, GRN haploinsufficiency, TMEM106B variation) drive TDP-43 dysfunction and synaptic failure; MAPT mutations drive tau misfolding with axonal and synaptic compromise; and glial activation amplifies neurodegeneration (https://doi.org/10.1186/s40035-024-00429-6 is a tau-focused background review; mechanistic points here from cited sources below) (huber2024mechanismsofneurodegeneration pages 57-60, saloner2025largescalenetworkanalysis pages 1-7, hsiaonakamoto2024alterationsinlysosomal pages 1-5, huber2024mechanismsofneurodegenerationa pages 79-82).
Recent systems–level CSF proteomics across autosomal-dominant FTLD (C9orf72, GRN, MAPT) shows increased RNA-splicing modules (notably in C9orf72, GRN), increased extracellular matrix modules (MAPT), and decreased synaptic/neuronal and autophagy modules, aligning in vivo fluid signatures with core mechanisms and suggesting hub proteins as potential biomarkers/targets (https://doi.org/10.21203/rs.3.rs-4103685/v1, Mar 2025) (saloner2025largescalenetworkanalysis pages 1-7).
1) Core Pathophysiology - Primary mechanisms - Proteinopathies: FTLD–TDP (~about half of cases), FTLD–tau (large fraction), FTLD–FUS (~minority) (synaptopathy review; mechanistic overview) (clayton2024synaptopathypresynapticconvergence pages 1-2, huber2024mechanismsofneurodegeneration pages 57-60). - Synaptic dysfunction: Early, convergent presynaptic deficits in vesicle priming, recycling, and local translation; TDP-43 loss-of-function reduces UNC13A and impairs priming, linking RNA-binding protein pathology to synaptic failure (https://doi.org/10.1093/brain/awae074, 2024; mechanistic synthesis) (clayton2024synaptopathypresynapticconvergence pages 1-2, huber2024mechanismsofneurodegeneration pages 57-60, huber2024mechanismsofneurodegenerationb pages 57-60). - Autophagy–lysosome dysfunction: GRN haploinsufficiency and TMEM106B risk alleles disrupt autophagosome–lysosome maturation, acidification and cargo clearance; in FTLD, autophagy modules are reduced in CSF network analyses (https://doi.org/10.1186/s12974-024-03039-1, Feb 2024; https://doi.org/10.21203/rs.3.rs-4103685/v1, Mar 2025) (sung2024progranulinhaploinsufficiencymediates pages 1-2, huber2024mechanismsofneurodegeneration pages 57-60, saloner2025largescalenetworkanalysis pages 1-7). - Nucleocytoplasmic transport impairment: Particularly in C9orf72 repeat expansion disease (loss-of-function and toxic gain-of-function via RNA foci and dipeptide repeat proteins) with downstream TDP-43 dyshomeostasis (https://doi.org/10.21203/rs.3.rs-4103685/v1, Mar 2025) (saloner2025largescalenetworkanalysis pages 1-7). - Neuroinflammation: Microglial and astrocytic activation; in GRN-related FTD, microglia show TDP-43 cytoplasmic aggregation with lysosomal abnormalities and complement C1q activation; glial biomarkers are elevated in biofluids (https://doi.org/10.1186/s12974-024-03039-1, Feb 2024; biofluid/tissue biomarker study) (sung2024progranulinhaploinsufficiencymediates pages 1-2, hsiaonakamoto2024alterationsinlysosomal pages 1-5, hsiaonakamoto2024alterationsinlysosomal pages 30-33).
TMEM106B–lysosome axis modulates TDP-43 dysfunction and C9orf72 DPR burden; UNC13A–synapse axis mediates TDP-43 loss-of-function at the presynapse (mechanistic consolidation) (huber2024mechanismsofneurodegeneration pages 57-60, huber2024mechanismsofneurodegenerationb pages 57-60, huber2024mechanismsofneurodegenerationa pages 57-60).
Cellular processes affected
2) Key Molecular Players - Genes/Proteins (HGNC symbols) - GRN (progranulin): Haploinsufficiency causes lysosomal dysfunction and microglial activation; human microglia from GRN-FTD show cytoplasmic TDP-43 aggregation, lipid droplet accumulation, and profound lysosomal abnormalities with complement C1q activation (https://doi.org/10.1186/s12974-024-03039-1, Feb 2024) (sung2024progranulinhaploinsufficiencymediates pages 1-2). - C9orf72: Hexanucleotide repeat expansions cause combined loss-of-function and gain-of-function (RNA foci, dipeptide-repeat proteins) that impair RNA metabolism, nucleocytoplasmic transport, proteostasis and lead to TDP-43 aggregation (https://doi.org/10.21203/rs.3.rs-4103685/v1, Mar 2025) (saloner2025largescalenetworkanalysis pages 1-7). - MAPT (tau): Mutations drive tau aggregation, extracellular matrix and synaptic signaling alterations (CSF proteomics) and axonal/synaptic compromise in FTLD–tau (https://doi.org/10.21203/rs.3.rs-4103685/v1, Mar 2025) (saloner2025largescalenetworkanalysis pages 1-7). - TARDBP (TDP-43): Aggregation and nuclear loss-of-function disrupt RNA splicing/transport; presynaptic effects via UNC13A dysregulation (review evidence) (huber2024mechanismsofneurodegeneration pages 57-60, clayton2024synaptopathypresynapticconvergence pages 1-2). - FUS: Defines a minority FTLD–FUS class (overview) (clayton2024synaptopathypresynapticconvergence pages 1-2, huber2024mechanismsofneurodegeneration pages 57-60). - TMEM106B: Genetic modifier in FTLD–TDP; risk alleles/filament accumulation associate with endolysosomal defects, impaired RNA transport/local translation, and heightened TDP-43 dysfunction; knockdown increases DPR accumulation and disrupts autophagosome–lysosome maturation (mechanistic synthesis) (huber2024mechanismsofneurodegeneration pages 57-60, huber2024mechanismsofneurodegenerationb pages 57-60, huber2024mechanismsofneurodegenerationa pages 57-60). - UNC13A: Presynaptic vesicle priming factor; TDP-43–dependent cryptic exon inclusion and poly-PR decrease UNC13A, linking TDP-43 pathology to synaptic failure (huber2024mechanismsofneurodegeneration pages 57-60, huber2024mechanismsofneurodegenerationb pages 57-60).
Synaptic proteins NPTX2, NPTXR (neuronal pentraxins), VGF: Reduced in CSF across FTD, most pronounced in MAPT carriers; some correlate with disease severity (https://doi.org/10.1101/2024.02.09.579529, 2024) (hsiaonakamoto2024alterationsinlysosomal pages 1-5, hsiaonakamoto2024alterationsinlysosomal pages 30-33).
Cell Types (CL terms; selected)
Oligodendrocytes: can harbor inclusions in FTLD–TDP subtypes (overview) (huber2024mechanismsofneurodegeneration pages 57-60).
Anatomical locations (UBERON terms; selected)
3) Biological Processes (for GO annotation; selected disrupted processes) - Protein aggregation, phase separation and inclusion formation (TDP-43, tau, FUS) (huber2024mechanismsofneurodegeneration pages 57-60, clayton2024synaptopathypresynapticconvergence pages 1-2). - RNA splicing/processing and RNA transport (TDP-43 loss-of-function; global RNA splicing module increases in CSF proteomics) (saloner2025largescalenetworkanalysis pages 1-7, huber2024mechanismsofneurodegeneration pages 57-60). - Nucleocytoplasmic transport (impaired in C9orf72 expansion disease) (saloner2025largescalenetworkanalysis pages 1-7). - Autophagy and lysosome organization/acidification; cargo trafficking (GRN/TMEM106B axis) (sung2024progranulinhaploinsufficiencymediates pages 1-2, huber2024mechanismsofneurodegeneration pages 57-60). - Synaptic vesicle priming/exocytosis and presynaptic homeostasis (UNC13A, vesicle cycle) (clayton2024synaptopathypresynapticconvergence pages 1-2, huber2024mechanismsofneurodegeneration pages 57-60). - Complement activation and innate immune signaling in glia (C1q, YKL-40 elevation; microglial activation) (sung2024progranulinhaploinsufficiencymediates pages 1-2, hsiaonakamoto2024alterationsinlysosomal pages 1-5, hsiaonakamoto2024alterationsinlysosomal pages 30-33). - Extracellular matrix remodeling (MAPT-associated CSF modules) (saloner2025largescalenetworkanalysis pages 1-7).
4) Cellular Components (selected) - Presynapse/synaptic vesicle pool; active zone (UNC13A-dependent priming) (clayton2024synaptopathypresynapticconvergence pages 1-2, huber2024mechanismsofneurodegeneration pages 57-60). - Lysosomes, late endosomes, autophagosomes and autolysosomes (GRN/TMEM106B-dependent maturation and acidification) (sung2024progranulinhaploinsufficiencymediates pages 1-2, huber2024mechanismsofneurodegeneration pages 57-60). - Stress granules and ribonucleoprotein assemblies (RNA-binding proteinopathies; overview) (huber2024mechanismsofneurodegeneration pages 57-60). - Nucleus and cytoplasm (TDP-43 nucleocytoplasmic mislocalization) (huber2024mechanismsofneurodegeneration pages 57-60, saloner2025largescalenetworkanalysis pages 1-7).
5) Disease Progression - Sequence of events (typical mechanistic cascade): genetic risk/trigger (e.g., C9orf72 expansion; GRN loss; MAPT mutation; TMEM106B risk) → proteinopathy (TDP-43/tau/FUS misfolding and mislocalization) → early presynaptic dysfunction (vesicle priming/turnover; local translation) → impaired autophagy–lysosome clearance and nucleocytoplasmic transport → reactive glial responses and complement signaling → progressive neuronal/synaptic loss and network disintegration in frontal/temporal systems, manifesting as bvFTD or PPA variants (synthesis from reviews and biomarker/proteomics data) (clayton2024synaptopathypresynapticconvergence pages 1-2, huber2024mechanismsofneurodegeneration pages 57-60, saloner2025largescalenetworkanalysis pages 1-7, hsiaonakamoto2024alterationsinlysosomal pages 1-5). - Subtypes/stages: FTLD–TDP subtyping (A–D) and mixed pathologies occur; autosomal-dominant FTLD shows genotype-associated CSF module shifts (e.g., RNA splicing↑ in GRN/C9; ECM↑ in MAPT) and synaptic/autophagy module↓; these shifts mirror progression toward synaptic failure and lysosomal compromise (https://doi.org/10.21203/rs.3.rs-4103685/v1, 2025) (saloner2025largescalenetworkanalysis pages 1-7, hsiaonakamoto2024alterationsinlysosomal pages 1-5).
6) Phenotypic Manifestations - Core clinical phenotypes: behavioral variant FTD (bvFTD: disinhibition, apathy, loss of empathy, compulsions), and primary progressive aphasia variants (semantic and non-fluent/agrammatic), reflecting selective degeneration of salience/semantic networks in frontal/anterior temporal systems (network-level account) (https://doi.org/10.15496/publikation-94419, 2024) (reinermann2024thefunctionalconnectivity pages 14-17). - Clinicopathological links and mechanisms: presynaptic synaptopathy correlates with early cognitive/behavioral dysfunction; TDP-43 loss-of-function impacts synaptic genes (UNC13A), while GRN and TMEM106B lysosome biology contributes to neuroinflammation and clearance failure; in MAPT, synaptic/ECM alterations are prominent (synthesis) (clayton2024synaptopathypresynapticconvergence pages 1-2, huber2024mechanismsofneurodegeneration pages 57-60, saloner2025largescalenetworkanalysis pages 1-7, hsiaonakamoto2024alterationsinlysosomal pages 1-5).
Gene/protein annotations with ontology terms (examples) - GRN (HGNC:4601): lysosomal protein; processes: lysosome organization, regulation of inflammatory response, autophagy; components: lysosome, late endosome; evidence: human microglia TDP-43 aggregation with lysosomal abnormalities, complement activation in GRN haploinsufficiency (https://doi.org/10.1186/s12974-024-03039-1, 2024) (sung2024progranulinhaploinsufficiencymediates pages 1-2). - C9orf72 (HGNC:28339): GTPase regulator/trafficking; processes: nucleocytoplasmic transport, RNA metabolism, proteostasis; components: nucleus, cytoplasm, nuclear pore; evidence: combined loss- and gain-of-function with TDP-43 aggregation (https://doi.org/10.21203/rs.3.rs-4103685/v1, 2025) (saloner2025largescalenetworkanalysis pages 1-7). - MAPT (HGNC:6893): microtubule-associated protein; processes: microtubule stabilization, synaptic signaling; components: axon, somatodendritic compartments; evidence: ECM↑ and synaptic signaling alterations in MAPT FTLD CSF networks (https://doi.org/10.21203/rs.3.rs-4103685/v1, 2025) (saloner2025largescalenetworkanalysis pages 1-7). - TARDBP/TDP-43 (HGNC:11577): RNA-binding protein; processes: RNA splicing/transport; components: nucleus, cytoplasm; evidence: presynaptic synaptopathy via UNC13A dysregulation (review) (huber2024mechanismsofneurodegeneration pages 57-60, clayton2024synaptopathypresynapticconvergence pages 1-2). - FUS (HGNC:4010): RNA-binding; processes: RNA metabolism, stress granules; components: nucleus, stress granules; evidence: minority FTLD–FUS class (overview) (huber2024mechanismsofneurodegeneration pages 57-60, clayton2024synaptopathypresynapticconvergence pages 1-2). - TMEM106B (HGNC:24797): lysosomal membrane protein; processes: autophagosome–lysosome fusion, lysosomal acidification; components: lysosome, endolysosomal system; evidence: genetic modifier; DPR clearance; endolysosomal disruption (huber2024mechanismsofneurodegeneration pages 57-60, huber2024mechanismsofneurodegenerationb pages 57-60). - UNC13A (HGNC:12535): presynaptic priming; processes: synaptic vesicle exocytosis; components: active zone; evidence: TDP-43–dependent vulnerability and synaptic dysfunction (huber2024mechanismsofneurodegeneration pages 57-60, huber2024mechanismsofneurodegenerationb pages 57-60).
Phenotype associations (examples; HP terms) - Behavioral disinhibition, apathy, loss of empathy, compulsive behaviors, executive dysfunction; expressive language deficits (semantic variant, non-fluent variant) (network/clinical synthesis) (reinermann2024thefunctionalconnectivity pages 14-17).
Cell type involvement (examples; CL terms) - Neuron (principal excitatory neuron), microglial cell, astrocyte, oligodendrocyte; endothelial/vascular involvement is under active study but not established by the evidence set cited here (clayton2024synaptopathypresynapticconvergence pages 1-2, sung2024progranulinhaploinsufficiencymediates pages 1-2, hsiaonakamoto2024alterationsinlysosomal pages 1-5).
Anatomical locations (UBERON terms) - Frontal lobe, temporal lobe, insula, anterior temporal pole; paralimbic fronto–insular–striatal network elements (reinermann2024thefunctionalconnectivity pages 14-17).
Chemical entities (CHEBI terms) - Glucosylsphingosine (GlcSph), ganglioside GM2, globoside GB3; NfL (protein biomarker), GFAP, YKL-40; neuronal pentraxins (NPTX2/NPTXR); VGF (hsiaonakamoto2024alterationsinlysosomal pages 1-5, hsiaonakamoto2024alterationsinlysosomal pages 30-33, huber2024mechanismsofneurodegenerationa pages 79-82).
Evidence items and key statistics - Pathological classes and convergence: Most FTD belongs to FTLD–TDP or FTLD–tau; FTLD–FUS is less common. Early presynaptic dysfunction is a convergent, likely initiating mechanism across genetic backgrounds (https://doi.org/10.1093/brain/awae074, 2024) (clayton2024synaptopathypresynapticconvergence pages 1-2, huber2024mechanismsofneurodegeneration pages 57-60). - TMEM106B modifies FTLD–TDP: risk alleles/filaments link to TDP-43 dysfunction and endolysosomal impairment; knockdown increases C9 DPRs and blocks autophagosome–lysosome maturation (mechanistic evidence compiled) (huber2024mechanismsofneurodegeneration pages 57-60, huber2024mechanismsofneurodegenerationb pages 57-60, huber2024mechanismsofneurodegenerationa pages 57-60). - GRN haploinsufficiency: human microglia from GRN-FTD show cytoplasmic TDP-43 aggregation, lysosomal abnormalities, complement C1q activation, and impaired phagocytosis (https://doi.org/10.1186/s12974-024-03039-1, Feb 2024) (sung2024progranulinhaploinsufficiencymediates pages 1-2). - CSF proteomics in genetic FTLD (n≈116 carriers vs 39 controls): RNA-splicing modules↑ (C9orf72, GRN), ECM modules↑ (MAPT), synaptic/neuronal and autophagy modules↓; signatures generalize to independent cohorts (https://doi.org/10.21203/rs.3.rs-4103685/v1, Mar 2025) (saloner2025largescalenetworkanalysis pages 1-7). - Biofluid/tissue biomarkers across FTD: plasma/CSF NfL↑ across forms (severity correlation); plasma GFAP↑ and CSF YKL-40↑ (notably in GRN and MAPT); CSF NPTX2/NPTXR↓ and VGF↓ (synaptic loss), strongest in MAPT; lysosomal lipids (GlcSph, GM2, GB3)↑ in disease-affected cortex; some markers (e.g., NPTXR) correlate with CDR+NACC FTLD severity (https://doi.org/10.1101/2024.02.09.579529, Feb 2024) (hsiaonakamoto2024alterationsinlysosomal pages 1-5, hsiaonakamoto2024alterationsinlysosomal pages 30-33, hsiaonakamoto2024alterationsinlysosomal pages 33-38).
Applications and real‑world implementations - Biomarker applications: NfL (plasma/CSF) as a prognostic and pharmacodynamic marker across FTLD; plasma GFAP and CSF YKL‑40 for glial activation; CSF neuronal pentraxins (NPTX2/NPTXR) for synaptic integrity; genotype‑specific lysosomal lipids (e.g., plasma GlcSph in GRN) for stratification and presymptomatic monitoring; AD biomarkers (Aβ42/40, p‑tau) to exclude AD copathology in differential diagnosis (https://doi.org/10.1101/2024.02.09.579529, 2024; biomarker review perspective) (hsiaonakamoto2024alterationsinlysosomal pages 1-5, huber2024mechanismsofneurodegenerationa pages 79-82). - Therapeutic directions informed by mechanisms: Targeting lysosomal biology (GRN replacement/augmentation; TMEM106B modulation), nucleocytoplasmic transport (C9orf72 pathways), and synaptic resilience (UNC13A/synaptic vesicle cycle) are rational avenues suggested by convergent mechanisms and CSF network signatures (https://doi.org/10.21203/rs.3.rs-4103685/v1, 2025; mechanistic syntheses) (saloner2025largescalenetworkanalysis pages 1-7, huber2024mechanismsofneurodegeneration pages 57-60, clayton2024synaptopathypresynapticconvergence pages 1-2).
Expert opinions and analysis from authoritative sources - A 2024 Brain review synthesizes convergent presynaptic synaptopathy across ALS–FTD, arguing it is an early and targetable hub across genetic backgrounds (https://doi.org/10.1093/brain/awae074, Mar 2024) (clayton2024synaptopathypresynapticconvergence pages 1-2). - Mechanistic syntheses emphasize TMEM106B and UNC13A as central modulators linking lysosomal/autophagy and presynaptic machinery to TDP‑43 pathology, recommending pathway‑focused biomarker development (huber2024mechanismsofneurodegeneration pages 57-60, huber2024mechanismsofneurodegenerationb pages 57-60). - Systems proteomics in genetic FTLD recommends network‑based biomarker panels and highlights RNA splicing, ECM, synaptic, and autophagy modules as translational anchors (https://doi.org/10.21203/rs.3.rs-4103685/v1, 2025) (saloner2025largescalenetworkanalysis pages 1-7).
Ontology‑ready annotations (examples) - Genes/Proteins (HGNC): GRN; C9orf72; MAPT; TARDBP; FUS; TMEM106B; UNC13A (sung2024progranulinhaploinsufficiencymediates pages 1-2, saloner2025largescalenetworkanalysis pages 1-7, huber2024mechanismsofneurodegeneration pages 57-60). - GO Biological Process: protein aggregation; RNA splicing; nucleocytoplasmic transport; autophagy; lysosome organization; synaptic vesicle exocytosis; microglial activation; complement activation (saloner2025largescalenetworkanalysis pages 1-7, huber2024mechanismsofneurodegeneration pages 57-60, sung2024progranulinhaploinsufficiencymediates pages 1-2, hsiaonakamoto2024alterationsinlysosomal pages 1-5). - GO Cellular Component: presynapse; synaptic vesicle; lysosome; autophagosome; nucleus; cytoplasm (clayton2024synaptopathypresynapticconvergence pages 1-2, huber2024mechanismsofneurodegeneration pages 57-60, sung2024progranulinhaploinsufficiencymediates pages 1-2). - Cell Types (CL): neuron; microglial cell; astrocyte; oligodendrocyte (clayton2024synaptopathypresynapticconvergence pages 1-2, sung2024progranulinhaploinsufficiencymediates pages 1-2, hsiaonakamoto2024alterationsinlysosomal pages 1-5, huber2024mechanismsofneurodegeneration pages 57-60). - Anatomical (UBERON): frontal lobe; temporal lobe; insula; anterior temporal pole (reinermann2024thefunctionalconnectivity pages 14-17). - Chemicals (CHEBI): glucosylsphingosine; ganglioside GM2; globoside GB3; neurofilament light; GFAP; YKL‑40; NPTX2; NPTXR; VGF (hsiaonakamoto2024alterationsinlysosomal pages 1-5, hsiaonakamoto2024alterationsinlysosomal pages 30-33, huber2024mechanismsofneurodegenerationa pages 79-82).
Notes on prevalence/incidence - Epidemiology varies by study/region; mechanistic reviews emphasize FTD as a leading cause of young‑onset dementia with high heritability and frequent autosomal‑dominant forms (network/overview context) (huber2024mechanismsofneurodegenerationa pages 33-38, reinermann2024thefunctionalconnectivity pages 14-17). Because robust, region‑specific incidence statistics were not directly available in the evidence set cited here, summary rates are not included; readers should refer to contemporary epidemiologic consortia for region‑specific denominators.
Cited sources (URLs and publication dates embedded above; ID mapping for statements) - Presynaptic convergence in ALS–FTD: Brain (Mar 2024): https://doi.org/10.1093/brain/awae074 (clayton2024synaptopathypresynapticconvergence pages 1-2). - Mechanism-focused syntheses with TMEM106B/UNC13A, FTLD class overview: 2024 synaptic–mechanism review (huber2024mechanismsofneurodegeneration pages 57-60, huber2024mechanismsofneurodegenerationb pages 57-60, huber2024mechanismsofneurodegenerationa pages 57-60). - GRN microglia TDP-43 aggregation and lysosomal abnormalities: J Neuroinflammation (Feb 2024): https://doi.org/10.1186/s12974-024-03039-1 (sung2024progranulinhaploinsufficiencymediates pages 1-2). - Systems CSF proteomics in genetic FTLD: Research Square (Mar 2025): https://doi.org/10.21203/rs.3.rs-4103685/v1 (saloner2025largescalenetworkanalysis pages 1-7). - Biofluid/tissue biomarkers across sporadic and genetic FTD (lysosomal lipids, glial and synaptic markers): bioRxiv (Feb 2024): https://doi.org/10.1101/2024.02.09.579529 (hsiaonakamoto2024alterationsinlysosomal pages 1-5, hsiaonakamoto2024alterationsinlysosomal pages 30-33, hsiaonakamoto2024alterationsinlysosomal pages 33-38). - Network/anatomical locus emphasis: doctoral thesis (May 2024): https://doi.org/10.15496/publikation-94419 (reinermann2024thefunctionalconnectivity pages 14-17).
Direct quotes (selected) - “iMGs from FTD–GRN patients with PGRN deficiency exhibited… cytoplasmic TDP-43 aggregation and… lysosomal abnormalities… mediated by complement C1q activation” (J Neuroinflammation, Feb 2024) (sung2024progranulinhaploinsufficiencymediates pages 1-2). - “This evidence indicates that presynaptic synaptopathy is an early and convergent event in frontotemporal dementia and amyotrophic lateral sclerosis” (Brain, Mar 2024) (clayton2024synaptopathypresynapticconvergence pages 1-2).
Limitations and gaps - Pathology-specific in vivo biomarkers (e.g., direct assays for TDP-43 or DPRs) remain under development; NfL and glial/synaptic markers offer staging and monitoring but are not pathology-specific. Future work should integrate network proteomics, genotype‑specific lipidomics, and synaptic panels to enhance differential diagnosis and target engagement (huber2024mechanismsofneurodegenerationa pages 79-82, saloner2025largescalenetworkanalysis pages 1-7, hsiaonakamoto2024alterationsinlysosomal pages 1-5).
References
(clayton2024synaptopathypresynapticconvergence pages 1-2): Emma L Clayton, Laura Huggon, Michael A Cousin, and Sarah Mizielinska. Synaptopathy: presynaptic convergence in frontotemporal dementia and amyotrophic lateral sclerosis. Brain, 147:2289-2307, Mar 2024. URL: https://doi.org/10.1093/brain/awae074, doi:10.1093/brain/awae074. This article has 19 citations and is from a highest quality peer-reviewed journal.
(huber2024mechanismsofneurodegeneration pages 57-60): N Huber. Mechanisms of neurodegeneration in frontotemporal dementia: focus on synaptic dysfunction. Unknown journal, 2024.
(saloner2025largescalenetworkanalysis pages 1-7): Rowan Saloner, Adam Staffaroni, Eric Dammer, Erik C.B. Johnson, Emily Paolillo, Amy Wise, Hilary Heuer, Leah Forsberg, Argentina Lario Lago, Julia Webb, Jacob Vogel, Alexander Santillo, Oskar Hansson, Joel Kramer, Bruce Miller, Jingyao Li, Joseph Loureiro, Rajeev Sivasankaran, Kathleen Worringer, Nicholas Seyfried, Jennifer Yokoyama, William Seeley, Salvatore Spina, Lea Grinberg, Lawren VandeVrede, Peter Ljubenkov, Ece Bayram, Andrea Bozoki, Danielle Brushaber, Ciaran Considine, Gregory Day, Bradford Dickerson, Kimiko Domoto-Reilly, Kelley Faber, Douglas Galasko, Daniel Geschwind, Nupur Ghoshal, Neill Graff-Radford, Chadwick Hales, Lawrence Honig, Ging-Yuek Hsiung, Edward Huey, John Kornak, Walter Kremers, Maria Lapid, Suzee Lee, Irene Litvan, Corey McMillan, Mario Mendez, Toji Miyagawa, Alexander Pantelyat, Belen Pascual, Henry Paulson, Leonard Petrucelli, Peter Pressman, Eliana Ramos, Katya Rascovsky, Erik Roberson, Rodolfo Savica, Allison Snyder, A. Campbell Sullivan, Carmela Tartaglia, Marijne Vandebergh, Bradley Boeve, Howie Rosen, Julio Rojas, Adam Boxer, and Kaitlin Casaletto. Large-scale network analysis of the cerebrospinal fluid proteome identifies molecular signatures of frontotemporal lobar degeneration. Research Square, Mar 2025. URL: https://doi.org/10.21203/rs.3.rs-4103685/v1, doi:10.21203/rs.3.rs-4103685/v1. This article has 19 citations.
(hsiaonakamoto2024alterationsinlysosomal pages 1-5): Jennifer Hsiao-Nakamoto, Chi-Lu Chiu, Lawren VandeVrede, Ritesh Ravi, Brittany Vandenberg, Jack De Groot, Buyankhishig Tsogtbaatar, Meng Fang, Paul Auger, Neal S. Gould, Filippo Marchioni, Casey A. Powers, Sonnet S. Davis, Jung H. Suh, Jamal Alkabsh, Hilary W. Heuer, Argentina Lario Lago, Kimberly Scearce-Levie, William W. Seeley, Bradley F. Boeve, Howard J. Rosen, Amy Berger, Richard Tsai, Gilbert Di Paolo, Adam L. Boxer, Akhil Bhalla, and Fen Huang. Alterations in lysosomal, glial and neurodegenerative biomarkers in patients with sporadic and genetic forms of frontotemporal dementia. bioRxiv, Feb 2024. URL: https://doi.org/10.1101/2024.02.09.579529, doi:10.1101/2024.02.09.579529. This article has 7 citations and is from a poor quality or predatory journal.
(huber2024mechanismsofneurodegenerationa pages 79-82): N Huber. Mechanisms of neurodegeneration in frontotemporal dementia: focus on synaptic dysfunction. Unknown journal, 2024.
(huber2024mechanismsofneurodegenerationb pages 57-60): N Huber. Mechanisms of neurodegeneration in frontotemporal dementia: focus on synaptic dysfunction. Unknown journal, 2024.
(sung2024progranulinhaploinsufficiencymediates pages 1-2): Wonjae Sung, Min-Young Noh, Minyeop Nahm, Yong Sung Kim, Chang-Seok Ki, Young-Eun Kim, Hee-Jin Kim, and Seung Hyun Kim. Progranulin haploinsufficiency mediates cytoplasmic tdp-43 aggregation with lysosomal abnormalities in human microglia. Journal of Neuroinflammation, Feb 2024. URL: https://doi.org/10.1186/s12974-024-03039-1, doi:10.1186/s12974-024-03039-1. This article has 20 citations and is from a peer-reviewed journal.
(hsiaonakamoto2024alterationsinlysosomal pages 30-33): Jennifer Hsiao-Nakamoto, Chi-Lu Chiu, Lawren VandeVrede, Ritesh Ravi, Brittany Vandenberg, Jack De Groot, Buyankhishig Tsogtbaatar, Meng Fang, Paul Auger, Neal S. Gould, Filippo Marchioni, Casey A. Powers, Sonnet S. Davis, Jung H. Suh, Jamal Alkabsh, Hilary W. Heuer, Argentina Lario Lago, Kimberly Scearce-Levie, William W. Seeley, Bradley F. Boeve, Howard J. Rosen, Amy Berger, Richard Tsai, Gilbert Di Paolo, Adam L. Boxer, Akhil Bhalla, and Fen Huang. Alterations in lysosomal, glial and neurodegenerative biomarkers in patients with sporadic and genetic forms of frontotemporal dementia. bioRxiv, Feb 2024. URL: https://doi.org/10.1101/2024.02.09.579529, doi:10.1101/2024.02.09.579529. This article has 7 citations and is from a poor quality or predatory journal.
(huber2024mechanismsofneurodegenerationa pages 57-60): N Huber. Mechanisms of neurodegeneration in frontotemporal dementia: focus on synaptic dysfunction. Unknown journal, 2024.
(reinermann2024thefunctionalconnectivity pages 14-17): Leonie Isabelle Reinermann. The functional connectivity of cortical degenerations that are relevant to apraxia in patients with genetic ftd. Unknown, May 2024. URL: https://doi.org/10.15496/publikation-94419, doi:10.15496/publikation-94419. This article has 0 citations.
(hsiaonakamoto2024alterationsinlysosomal pages 33-38): Jennifer Hsiao-Nakamoto, Chi-Lu Chiu, Lawren VandeVrede, Ritesh Ravi, Brittany Vandenberg, Jack De Groot, Buyankhishig Tsogtbaatar, Meng Fang, Paul Auger, Neal S. Gould, Filippo Marchioni, Casey A. Powers, Sonnet S. Davis, Jung H. Suh, Jamal Alkabsh, Hilary W. Heuer, Argentina Lario Lago, Kimberly Scearce-Levie, William W. Seeley, Bradley F. Boeve, Howard J. Rosen, Amy Berger, Richard Tsai, Gilbert Di Paolo, Adam L. Boxer, Akhil Bhalla, and Fen Huang. Alterations in lysosomal, glial and neurodegenerative biomarkers in patients with sporadic and genetic forms of frontotemporal dementia. bioRxiv, Feb 2024. URL: https://doi.org/10.1101/2024.02.09.579529, doi:10.1101/2024.02.09.579529. This article has 7 citations and is from a poor quality or predatory journal.
(huber2024mechanismsofneurodegenerationa pages 33-38): N Huber. Mechanisms of neurodegeneration in frontotemporal dementia: focus on synaptic dysfunction. Unknown journal, 2024.